Evaxion AS Stock Price, News & Analysis

Evaxion Biotech A/S (NASDAQ: EVAX) has reported promising results from its phase 2 trial of EVX-01, its lead cancer vaccine candidate. The interim analysis shows a 69% Overall Response Rate, with 11 out of 16 patients experiencing objective clinical responses. Notably, 15 out of 16 patients showed tumor reduction. The trial combines EVX-01 with MSD's anti-PD-1 therapy, KEYTRUDA®, in advanced melanoma patients.

The complete one-year dataset will be presented at the ESMO Congress 2024 in Barcelona. Evaxion's CEO, Christian Kanstrup, expressed excitement about the data, emphasizing its support for EVX-01's clinical profile and the AI-Immunology™ platform's predictive capabilities. The company will host a webinar on September 18, 2024, featuring Professor Georgina V. Long to discuss the trial results and challenges in advanced melanoma treatment.

Evaxion Biotech A/S (NASDAQ: EVAX) has announced promising pre-clinical proof-of-concept data for its EVX-B2 mRNA Gonorrhea vaccine candidate. The data shows that the vaccine triggers a targeted immune response leading to the elimination of gonorrhea bacteria. This validates Evaxion's AI-Immunology™ platform as delivery modality agnostic, applicable across different vaccine modalities.

The results, presented at the 18th Vaccine Congress in Lisbon, demonstrate the potential of AI-Immunology™ in developing treatments for bacterial diseases. EVX-B2 was initially designed as a protein-based vaccine, and this new data for the mRNA version further substantiates the platform's versatility. The research was conducted in collaboration with Afrigen Biologics.

CEO Christian Kanstrup highlighted this milestone as part of Evaxion's 2024 strategy execution, emphasizing the platform's value proposition for partners. With no existing Gonorrhea vaccine, EVX-B2 represents a potentially groundbreaking treatment opportunity.

Evaxion Biotech A/S (NASDAQ: EVAX) has released its Q2 2024 financial results and business update. Key highlights include:

- Ongoing partnership discussions as part of multi-partner approach
- Positive Phase 2 immune data for EVX-01 presented at ASCO
- On track for Phase 2 one-year clinical data readout at ESMO Congress 2024
- Improved performance of AI-Immunology™ platform
- Cash position of $8.0 million as of June 30, 2024
- Net loss of $6.2 million for Q2 2024

The company expects its cash to fund operations into February 2025 but requires additional income or funding to continue as a going concern. Evaxion is working to regain Nasdaq compliance by November 4, 2024.

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines, has announced it will provide a business update and report second quarter 2024 financial results on August 14, 2024, before the Nasdaq-CM opens. The company's Executive Management will host a conference call and webcast at 14:30 CEST/08:30 EDT on the same day to present the update and results, as well as take questions. This event is free and open to the public. Interested parties can register in advance to receive dial-in details and a unique pin code for the conference call. A webcast link is also provided, and a recording will be available on Evaxion's website shortly after the event.

Evaxion Biotech A/S (NASDAQ: EVAX) will present one-year clinical efficacy data from its Phase 2 study on lead cancer vaccine candidate, EVX-01, at the ESMO Congress 2024 in September. EVX-01 is a personalized therapy for advanced melanoma, developed using Evaxion's AI-Immunology™ platform. The presentation, selected by the ESMO Congress Scientific Committee, will take place on September 14, 2024, in Barcelona, Spain.

CEO Christian Kanstrup emphasized the significance of this milestone, highlighting the opportunity to showcase their data to a global audience of experts and potential partners. The innovative approach aims to enhance treatment efficacy by targeting the unique genetic makeup of individual tumors.

Evaxion Biotech A/S (NASDAQ: EVAX) has unveiled improved performance of its key AI-Immunology™ building block, EvaxMHC, at the 32nd Intelligent Systems for Molecular Biology conference. The advancements in EvaxMHC are expected to enhance Evaxion's ability to accurately predict vaccine targets for personalized and precision vaccines in cancer and infectious diseases.

The improvements include:

• Utilization of a state-of-the-art deep-learning framework
• Creation of a unified representation for MHC class I and II molecules
• Implementation of a deep transformer encoder-decoder architecture
• Adoption of a generative adversarial network (GAN) pretraining mechanism

These enhancements have led to improved vaccine designs demonstrated in preclinical studies, particularly for MHC class II molecules, which have historically been challenging to predict accurately.

Evaxion Biotech, a clinical-stage TechBio company, has made significant progress in the first half of 2024. They raised $15 million in a public offering, with MSD GHI becoming the largest shareholder. Collaborations with MSD for vaccine development are on track, with completion expected in the second half of 2024. The company showcased its AI-Immunology™ platform at an R&D Day in March, gaining interest from potential partners. In April, the first patient completed dosing in the Phase 2 trial of EVX-01 for metastatic melanoma, with promising immune data presented in June. The company aims to achieve business development income matching their $14 million operational cash burn and is advancing discussions with potential partners. Their focus remains on developing AI-powered vaccines to save and improve lives.

Evaxion Biotech announced positive feedback from an International Preliminary Report on Patentability (IPRP) for its AI-based method to identify novel cancer vaccine targets. This patent application (PCT/EP2022/086444) involves a unique approach to recognizing tumor vaccine targets derived from Endogenous Retroviruses (ERVs) using their proprietary AI-Immunology™ platform.

The feedback underscores the novelty and inventiveness of Evaxion's claims, enhancing the company's position in the personalized cancer vaccine field. The endorsement by the World Intellectual Property Organization (WIPO) confirms the patent's promising prospects. CEO Christian Kanstrup emphasized the importance of this validation in advancing Evaxion's innovative cancer treatments and strengthening their intellectual property portfolio as part of a multi-partner strategy.

Evaxion has published Phase 1 study data for its AI-designed personalized cancer vaccine, EVX-01, in the Journal for ImmunoTherapy of Cancer. The study showed a 67% objective response rate (ORR) in patients with metastatic melanoma, with eight out of 12 patients showing clinical responses — six partial and two complete. EVX-01, co-administered with anti-PD-1 therapy, did not cause serious vaccine-related adverse events. The results validate the precision of Evaxion's AI-Immunology™ platform.

Phase 2 of the EVX-01 program is underway, with 71% of administered neoantigens inducing specific T-cell responses, as presented at ASCO. The one-year efficacy readout is expected in Q3 2024. CEO Christian Kanstrup expressed optimism about these promising results.